 Braxia Scientific Corp. CSE:BRAX, OTC:BRAXF announced that it has received Health Canadas approval to provide psilocybin-assisted therapy to a patient with major depressive disorder in Ontario through its wholly-owned subsidiary the Canadian Rapid Treatment Centre of Excellence CRTCE. The company said the approval was granted under the recently amended Health Canada Special Access Program SAP, which was updated on January 5, 2022, to include access to psychedelic compounds on a case-by-case basis outside psychedelic trials. 